Shukra Pharmaceuticals' Q2 FY 2026-27 Quarterly Results

Result Summary

• Shukra Pharmaceuticals Ltd reported a 86.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 490.0%.
• Its expenses for the quarter were up by 357.6% QoQ and 264.7% YoY.
• The net profit decreased 1.9% QoQ and increased 434.0% YoY.
• The earnings per share (EPS) of Shukra Pharmaceuticals Ltd stood at 0.29 during Q2 FY 2026-27.

Financial Statments for Q2 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Shukra Pharmaceuticals Ltd operates in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of pharmaceutical products. The company is known for its production of a wide range of pharmaceutical formulations and bulk drugs. While specific recent developments are not available from the provided data, Shukra Pharmaceuticals Ltd is likely involved in both domestic and international markets, given the typical scope of operations for companies in this industry. The company may also engage in research and development efforts to expand its product offerings and improve existing formulations, although further details are not specified in the current dataset.

Revenue

In Q2FY27, Shukra Pharmaceuticals Ltd reported a total income of ₹44.78 crores, showcasing a substantial increase from ₹24.06 crores in Q1FY27 and ₹7.59 crores in Q2FY26. The quarter-over-quarter (QoQ) growth rate for total income is 86.1%, while the year-over-year (YoY) increase is an impressive 490.0%. This significant growth in revenue over both the previous quarter and the same quarter last year highlights a major shift in the company’s revenue-generating capabilities during the analyzed period. The data suggests a remarkable increase in revenue streams, possibly due to expanded sales volume, introduction of new products, or other operational improvements.

Profitability

Shukra Pharmaceuticals Ltd's profitability metrics indicate a robust performance. The Profit Before Tax (PBT) for Q2FY27 stands at ₹17.83 crores compared to ₹18.17 crores in Q1FY27 and ₹0.20 crores in Q2FY26. The QoQ change shows a slight decline of 1.9%, whereas the YoY growth is an extraordinary 8815.0%. The Profit After Tax (PAT) in Q2FY27 is ₹12.71 crores, slightly down from ₹12.96 crores in Q1FY27 but significantly higher than the ₹2.38 crores reported in Q2FY26, with a YoY increase of 434.0%. Earnings Per Share (EPS) also reflect this trend, with a slight decrease QoQ of 3.3% and a substantial YoY growth of 480.0%. These metrics demonstrate substantial profitability improvements over the year, despite minor QoQ reductions.

Operating Metrics

The total expenses in Q2FY27 for Shukra Pharmaceuticals Ltd were reported at ₹26.95 crores, which represents a significant increase from ₹5.89 crores in Q1FY27 and ₹7.39 crores in Q2FY26. The QoQ increase in expenses is 357.6%, while the YoY rise is 264.7%. Despite this rise in expenses, the company maintained a strong Profit Before Tax and Profit After Tax, indicating effective revenue generation. The tax expense for Q2FY27 was reported at ₹5.12 crores, showing a slight decrease from ₹5.21 crores in Q1FY27 and a notable change from negative tax in Q2FY26, with a YoY percentage change of -334.9%. This data indicates a shift in the company's tax liabilities, possibly due to changes in taxable income or applicable tax laws.